Content contributed by the Alzheimers Association A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported recently at the Alzheimers Association International Conference (AAIC) 2024, in Philadelphia and online
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities
The Need for New Real-World Evidence The sharp increase in perinatal GLP-1 RA use underscores the urgent demand for comprehensive, evidence-based safety data
Ketones cross the blood-brain barrier, providing 70% of the brains fuel by day 2
Yu S, Li Z, Zhang Q, Wang R, Zhao Z, Ding W, et al